SPRY241220P15000
- 1.45
- -0.19-11.59%
ARS Pharmaceuticals Newsroom
Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
ARS Pharmaceuticals (SPRY) Initiated With a Buy at Cantor Fitzgerald
ARS Pharmaceuticals Is Maintained at Outperform by Leerink Partners
ARS Pharmaceuticals Analyst Ratings
ARS Pharmaceuticals' Market Expansion and Strategic Positioning Affirm Buy Rating
ARS Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Initiates ARS Pharmaceuticals(SPRY.US) With Buy Rating, Announces Target Price $30
Leerink Partners Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $20
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $22
ARS Pharmaceuticals Analyst Ratings
ARS Pharmaceuticals Price Target Announced at $18.00/Share by Raymond James
ARS Pharmaceuticals Analyst Ratings
Raymond James Initiates ARS Pharmaceuticals(SPRY.US) With Buy Rating, Announces Target Price $18
Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Buy Rating on ARS Pharmaceuticals Amid Strong Neffy Approval Prospects and Indication Expansion
Ars Pharmaceuticals' Merger May Limit Use of Net Operating Losses, Impacting Future Financials
ARS Pharmaceuticals Analyst Ratings
Neffy's Market Potential and ARS Pharmaceuticals' Buy Rating Reinforced by Clinical Success